MGMel Greaves

Mel Greaves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mel Greaves has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony M. Ford

    From the Leukaemia Research Fund Centre, Institute of Cancer Research, London, United Kingdom

    7 shared publications
  • Ana-Teresa Maia

    University of Algarve

    2 shared publications
  • Elisabeth R. Van Wering

    From the Leukaemia Research Fund Centre, Institute of Cancer Research, London, UK; the Dutch Childhood Leukemia Study Group (DCLSG), The Hague, The Netherlands; and the Beatrix Children’s Hospital, University of Groningen, Groningen, The Netherlands

    2 shared publications
  • Joseph L. Wiemels

    From the Leukaemia Research Fund Centre, Institute of Cancer Research, London, United Kingdom

    2 shared publications
  • Osborn B. Eden

    From the Leukaemia Research Fund Centre, Institute of Cancer Research, Chester Beatty Laboratories, London; the Cytogenetics Laboratory, Department of Haematology, Royal Free Hospital, London; the Immunogenetics Laboratory, St Mary's Hospital, Manchester; and the Academic Unit of Paediatric Oncology, Christie Hospital and Royal Manchester Children's NHS Trusts, United Kingdom

    2 shared publications
  • Aleida Postma

    From the Leukaemia Research Fund Centre, Institute of Cancer Research, London, UK; the Dutch Childhood Leukemia Study Group (DCLSG), The Hague, The Netherlands; and the Beatrix Children’s Hospital, University of Groningen, Groningen, The Netherlands

    1 shared publication

Latest Publications

    • 1 January 2004
      • No. 157,p. 351-72

    Biological models for leukaemia and lymphoma.

    by Mel F Greaves

    Blood-cell cancers (leukaemias, lymphomas and myeloma) are a very diverse group of neoplasms derived from a variety of stem cells at different hierarchical levels of haemopoietic and lymphoid cell development. This biological heterogeneity is likely to be associated with a variety of different etiological mechanisms. Correspondingly, a large number of inherited normal allelic variations might be expected to contribute to risk. Leukaemias alone have more than 200 different acquired (non-constitutive) molecular abnormalities but some are much more prevalent than others and are associated with biological subtypes with distinctive clinical or prognostic features. Balanced chromosome translocations are very common, together with simple gains or losses of chromosomes. Gene deletions and mutations are also relatively common, especially in more advanced disease. In several types of leukaemia and lymphoma, a transition from benign to malignant status can be tracked together with concurrent accrual of additional molecular abnormalities (e.g. chronic myeloid leukaemia evolving into blast crisis and follicular lymphoma becoming diffuse). The covert preclinical natural history of paediatric leukaemia has been revealed by 'back-tracking' using chromosomal translocation-gene-rated fusion gene sequences as clone-specific stable, specific and sensitive markers. Studies in identical twins, in archived neonatal blood spots of patients and in normal newborn cord bloods all support the contention that chromosomal translocations often initiate leukaemia in utero. Twin concordance rates (and animal modelling) suggest that further secondary genetic changes and exposures postnatally are, however, critical and this is endorsed by the finding that leukaemic fusion genes are present in normal newborn infants at a rate that far exceeds the cumulative risk of leukaemia. The natural history of leukaemic subtypes provides a useful framework for molecular epidemiological studies and significant advances have been made in this respect with infant and childhood acute lymphoblastic leukaemia.


  • Top Cited Papers

    Leukemia in twins: lessons in natural history

    by Mel F. Greaves, Ana Teresa Maia, Joseph L. Wiemels, Anthony M. Ford

    Identical infant twins with concordant leukemia were first described in 1882, and since that time many such pairs of infants and older children have been described. It has long been recognized that this situation offers a unique opportunity to identify aspects of the developmental timing, natural history, and molecular genetics of pediatric leukemia in general. We reviewed both the older literature and more recent molecular biologic studies that have uncovered the basis of concordance of leukemia. Molecular markers of clonality, including unique, genomic fusion gene sequences, have provided unequivocal evidence that twin pairs of leukemia have a common clonal origin. The only plausible basis for this, first suggested more than 40 years ago, is that following initiation of leukemia in one twin fetus, clonal progeny spread to the co-twin via vascular anastomoses within a single, monochorionic placenta. This explanation has been endorsed by the identification of clonotypic gene fusion sequences in archived neonatal blood spots of individuals who subsequently developed leukemia. These analyses of twin leukemias have thrown considerable light on the natural history of disease. They reveal a frequent prenatal origin and an early or initiating role for chromosome translocations. Further, they provide evidence for a variable and often protracted latency and the need, in childhood acute lymphoblastic leukemia (ALL)/acute myeloblastic leukemia (AML), for further postnatal exposures and/or genetic events to produce clinical disease. We argue that these insights provide a very useful framework for attempts to understand etiologic mechanisms. (Blood. 2003;102:2321-2333)


  • Top Cited Papers
    Open Access

    Chromosome translocations and covert leukemic clones are generated during normal fetal development

    by Hiroshi Mori, Susan M. Colman, Zhijian Xiao, Anthony M. Ford, Lyn E. Healy, Craig Donaldson, Jill M. Hows, Cristina Navarrete, Mel Greaves

    Studies on monozygotic twins with concordant leukemia and retrospective scrutiny of neonatal blood spots of patients with leukemia indicate that chromosomal translocations characteristic of pediatric leukemia often arise prenatally, probably as initiating events. The modest concordance rate for leukemia in identical twins (≈5%), protracted latency, and transgenic modeling all suggest that additional postnatal exposure and/or genetic events are required for clinically overt leukemia development. This notion leads to the prediction that chromosome translocations, functional fusion genes, and preleukemic clones should be present in the blood of healthy newborns at a rate that is significantly greater than the cumulative risk of the corresponding leukemia. Using parallel reverse transcriptase–PCR and real-time PCR (Taqman) screening, we find that the common leukemia fusion genes, TEL-AML1 or AML1-ETO , are present in cord bloods at a frequency that is 100-fold greater than the risk of the corresponding leukemia. Single-cell analysis by cell enrichment and immunophenotype/fluorescence in situ hybridization multicolor staining confirmed the presence of translocations in restricted cell types corresponding to the B lymphoid or myeloid lineage of the leukemias that normally harbor these fusion genes. The frequency of positive cells (10 −4 to 10 −3 ) indicates substantial clonal expansion of a progenitor population. These data have significant implications for the pathogenesis, natural history, and etiology of childhood leukemia.


  • Science, medicine, and the future: Childhood leukaemia

    by Mel Greaves

    Molecular genetics provide exciting new insights into the pathogenesis of childhood leukaemia The risk of any child developing acute leukaemia is about 1 in 2000 with 400-450 new cases a year in the United Kingdom. Cure rates approaching 75% can be achieved with combination chemotherapy, but this figure disguises success rates that vary from 10% to 90% with the different biological subtypes of the disease. In this review I discuss how new insights into the underlying molecular biology of leukaemia have changed our understanding of the disease. Not only is there the prospect of better treatment and the introduction of new biologically based therapies, but, as the causes of disease are being unravelled, the possibility of prevention may not just be wishful thinking. #### Summary points Different chromosomal and gene abnormalities in leukaemia define biological subsets of disease with prognostic importance Chromosome translocations generate chimeric fusion genes, which provide stable sensitive markers that are unique for each patient's leukaemic clone and can be used to track its origins and response to treatment The common chromosome translocations in childhood leukaemia seem to initiate disease and often arise prenatally One or more postnatal genetic alterations are also needed for leukaemia development, and in childhood acute lymphoblastic leukaemia these may be caused by abnormal immune responses to infection Proteins coded by fusion genes operate principally by blocking cell differentiation in leukaemic cells and provide potential targets for new treatments This article is based on information and views published from my laboratory plus comprehensive, prospective screening of leading journals for leukaemia and cancer research. It has long been recognised that childhood leukaemia is not one homogeneous disease. The major morphological division into acute lymphoblastic leukaemia and acute myeloblastic leukaemia is supplemented by the identification of a range of subsets based on gene expression, antigens that delineate cell …


  • Open Access

    Commentary: Birth order and risk of childhood acute lymphoblastic leukaemia (ALL)

    by Mf Greaves

    In this issue of the International Journal of Epidemiology, Dockerty and colleagues1 report a case-control study in which a number of parental, familial and social factors were evaluated in relation to risk of different childhood cancers. The rationale of the study is a rather curious mix of four different hypotheses, only loosely interconnected by the parameters studied. But it does have two outstanding features—its very large size and a design that minimizes selection bias. These provide the potential for robust statistical inquisition of associations, or the lack thereof. Cases (age 0–14 years) total almost 11 000 including 3878 leukaemias, all accrued from the British National Registry of Childhood Tumours for the period 1968–1986. Controls were selected from the Office of Population Censuses and Surveys (OPCS, now Office for National Statistics) birth data and matched for gender, date of birth (6-month periods) and birth registration sub-district.


  • Open Access

    Origins of “late” relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes

    by Anthony M. Ford, Karin Fasching, E. Renate Panzer-GrümAyer, Margit Koenig, Oskar A. Haas, Mel F. Greaves

    Approximately 20% of childhood B-precursor acute lymphoblastic leukemia (ALL) has a TEL-AML1 fusion gene, often in association with deletions of the nonrearranged TEL allele.TEL-AML1 gene fusion appears to be an initiating event and usually occurs before birth, in utero. This subgroup of ALL generally presents with low- or medium-risk features and overall has a very good prognosis. Some patients, however, do have relapses late or after the cessation of treatment, at least on some therapeutic protocols. They usually achieve sustained second remissions. Posttreatment relapses, or even very late relapses (5-20 years after diagnosis), in childhood ALL are clonally related to the leukemic cells at diagnosis (by IGH or T-cell receptor [TCR] gene sequencing) and are considered, therefore, to represent a slow re-emergence or escape of the initial clone seen at diagnosis. Microsatellite markers and fluorescence in situ hybridization identified deletions of the unrearranged TEL allele and IGH/TCR gene rearrangements were analyzed; the results show that posttreatment relapse cells in 2 patients with TEL-AML1–positive ALL were not derived from the dominant clone present at diagnosis but were from a sibling clone. In contrast, a patient who had a relapse while on treatment with TEL-AML1 fusion had essentially the sameTEL deletion, though with evidence for microsatellite instability 5′ of TEL gene deletion at diagnosis, leading to extended 5′ deletion at relapse. It is speculated that, in some patients, combination chemotherapy for childhood ALL may fail to eliminate a fetal preleukemic clone with TEL-AML1 and that a second, independent transformation event within this clone after treatment gives rise to a new leukemia masquerading as relapse.


  • Open Access

    Molecular tracking of leukemogenesis in a triplet pregnancy

    by Ana Teresa Maia, Anthony M. Ford, G. Reza Jalali, Christine J. Harrison, G. Malcolm Taylor, Osborn B. Eden, Mel F. Greaves

    The occurrence of childhood acute lymphoblastic leukemia (ALL) in 2 of 3 triplets provided a unique opportunity for the investigation of leukemogenesis and the natural history of ALL. The 2 leukemic triplets were monozygotic twins and shared an identical, acquiredTEL-AML1 genomic fusion sequence indicative of a single-cell origin in utero in one fetus followed by dissemination of clonal progeny to the comonozygotic twin by intraplacental transfer. In accord with this interpretation, clonotypic TEL-AML1 fusion sequences could be amplified from the archived neonatal blood spots of the leukemic twins. The blood spot of the third, healthy, dizygotic triplet was also fusion gene positive in a single segment, though at age 3 years, his blood was found negative by sensitive polymerase chain reaction (PCR) screening for the genomic sequence and by reverse transcription–PCR. Leukemic cells in both twins had, in addition toTEL-AML1 fusion, a deletion of the normal, nonrearrangedTEL allele. However, this genetic change was found by fluorescence in situ hybridization to be subclonal in both twins. Furthermore, mapping of the genomic boundaries of TELdeletions using microsatellite markers indicated that they were individually distinct in the twins and therefore must have arisen as independent and secondary events, probably after birth. These data support a multihit temporal model for the pathogenesis of the common form of childhood leukemia.